Skip to content

Clinical Study to Assess Efficacy and Safety of Amiodarone in Treating Patients With Ebola. Virus Disease (EVD) in Sierra Leone. EASE (EMERGENCY Amiodarone Study Against Ebola)

Clinical Study to Assess Efficacy and Safety of Amiodarone in Treating Patients With Ebola.

Status
Withdrawn
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02307591
Acronym
EASE
Enrollment
0
Registered
2014-12-04
Start date
2014-12-31
Completion date
2015-07-31
Last updated
2015-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ebola Virus Disease

Brief summary

The purpose of this study is to evaluate the efficacy and safety of amiodarone in the treatment of patients afflicted with Ebola virus disease.

Interventions

DRUGBest Supportive Care

Dehydration Ringer's lactate solution or normal saline intravenously Electrolytes should be monitored at regular intervals and corrected as long as vomiting and/or diarrhoea persist Fever intravenous Paracetamol Antimicrobial treatment Prophylactic 5-days course with Ampicillin should be used Pain Paracetamol,Tramadol or Pentazocine Central nervous system disturbances If a patient is restless or confused, prescribe a light sedation utilizing Midazolam, Propofol or Ketamine, preferably in association with Diazepam or Midazolam Seizures Diazepam Vomiting antiemetic medications may provide some relief and facilitate the rehydration Dyspepsia in adults, Omeprazole Diarrhoea in adults, Loperamide Acute bleeding leading to signs of haemorrhagic shock should be treated with whole blood transfusion and supportive care. Patients haemodynamically stable should not be transfused if the Hb level is \>7 mg% Septic shock intensive support care Malaria in case of positive initial test, Artesunate

DRUGBest Supportive Care + Amiodarone

This treatment will be provided to patients in the experimental arm only in addition to best supportive care scheme . During the first 3 days of treatment, the drug must be administered in Glucose 5% solution. Deliver through the largest possible vein inserting a long catheter (if possible a CVP line). Day 1. Dose: 20 mg/kg/die i.v. deliver a loading dose of 5mg/kg in the 1st hour, followed by continuous infusion during the remaining 23 hours. Example: 20 mg /kg of Amiodarone in 500 cc of Glucose 5%. Deliver 125 ml during the 1st hour followed by 16 ml/hour for the remaining 23 hours. Day 2 - Day 3. Dose: 20 mg/kg/die i.v. Continuous infusion over 24 hrs. Example: Glucose 5% 500 ml containing 20 mg/kg of Amiodarone (infusion speed = 21 ml/hour). Day 4 to Day 10. If no significant diarrhea and/or vomiting, shift to oral intake of Amiodarone as follows: * Adults: 200 mg tablets, 3 times a day, according to the body weight (30mg/Kg) * Children \< 29 kg: 5 mg/kg 3 times a day

Sponsors

Emergency NGO Onlus
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
2 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patient admitted to the Emergency ETC at Goderich with a clinical diagnosis of Ebola virus disease; * patient who consent to participate in the study.

Exclusion criteria

* negative RT-PCR tests for Ebola virus * age \<2 years * state of shock upon admission * onset of fever for more than 6 days * Glasgow Coma Scale \<12 * known contraindications to administration of amiodarone * positive for HIV antibodies.

Design outcomes

Primary

MeasureTime frame
All cause mortality10 days

Secondary

MeasureTime frame
Viral loadDay 2, 5, 10 and 14
Lymphocyte countDay 2, 5, 10 and 14
IgM anti-Ebola virus antibody titerDay 2, 5, 10 and 14
Adverse eventsDay 1-10 , 14
Serum concentration of amiodaroneDay 2, 5, 10 and 14
Vital statusDay 14 and 30
IgG anti-Ebola virus antibody titerDay 2, 5, 10 and 14

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026